A single-dose, randomized, open-label, two-period crossover bioequivalence study of a fixed-dose pediatric combination of lamivudine 40-mg, nevirapine 70-mg, and stavudine 10-mg tablet for oral suspension with individual liquid formulations in healthy adult male volunteers

Clinical Therapeutics

Volumn 29, Issue 12, 2007, Pages 2677-2684

  Monif, Tausif ^a   Rao Thudi, Nageshwar ^b   Koundinya Tippabhotla, Sudhakar ^a   Khuroo, Arshad ^a   Marwah, Amit ^a   Kumar Shrivastav, Vikesh ^a   Tandon, Monika ^a   Raghuvanshi, Rajeev ^a   Biswal, Shibadas ^a  

^a Ranbaxy Laboratories Limited   (India)

^b Ranbaxy Pharmaceuticals Canada Inc   (Canada)

Author keywords

ARV; FDC; lamivudine; nevirapine; pediatric; stavudine

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; BODY HEIGHT; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-HIV AGENTS; CROSS-OVER STUDIES; DRUG COMBINATIONS; FASTING; HUMANS; INDIA; LAMIVUDINE; MALE; NEVIRAPINE; STAVUDINE; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 38049086118     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.12.028     Document Type: Article

References (16)

1. WHO Library Cataloguing-in-Publication Data. AIDS epidemic update: Special report on HIV/AIDS (2006), WHO/UNAIDS. www.unaids.org Accessed March 16, 2007
2. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: Towards universal access. Recommendations for a public health approach (2006), WHO. http://www.who.int/hiv/pub/guidelines/art/en/index.html Accessed March 15, 2007
3. Calmy A., Pinoges L., Szumilin E., et al., for theMédicins Sans Frontieres. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: Multicentric observational cohort. AIDS 20 (2006) 1163-1169
4. Havens P., Gibb D., and for the American Academy of Pediatrics Committee on Pediatric AIDS. Section on International Child Health. Increasing antiretroviral drug access for children with HIV infection. Pediatrics 119 (2007) 838-845
5. O'Brien D., Sauvageot D., Zachariah R., Humblet P., and for the Medicins Sans Frontieres. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 20 (2006) 1955-1960
6. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int Accessed March 19, 2007
7. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects (March 26, 2007). http://www.wma.net/e/policy/b3.htm Accessed
8. Life Insurance Company of India. Standard Height and Weight for Indian Men & Women.
9. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry: Bioanalytical method validation (May 2001). http://www.fda.gov/cder/guidance/4252fnl.htm Accessed March 17, 2007
10. Karch F., and Lasagna L. Adverse drug reactions. A critical review. JAMA 234 (1975) 1236-1241
11. King J., Kimberlin D., Aldrovandi G., and Acosta E. Antiretroviral pharmacokinetics in the pediatric population. Clin Pharmacokinet 41 (2002) 1115-1133
12. Gandhi M., Aweeka F., Greenblatt R., and Blaschke T. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44 (2004) 499-523
13. Center for Drug Evaluation and Research (CDER), US FDA. Industry Guidance, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations (March 16, 2007). http://www.fda.gov/cder/guidance/5356fnl.pdf Accessed
14. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 63 (2003) 2555-2574
15. Yozviak J., Doerfler R., and Woodward W. Effectiveness and tolerability of nevirapine, stavudine and lamivudine in clinical practice. HIV Clin Trials 2 (2001) 474-476
16. Hoffmann C., and Mulcahy F. HIV therapy 2006. In: Hoffmann C., Rockstroh J., and Kamps B. (Eds). HIV Medicine 2006. 14th ed (2006), Flying Publisher, Paris, France 89-278. http://www.hivmedicine.com Accessed April 1, 2007